Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  1. Brain Abscess and Risk of Cancer: A Nationwide Population-Based Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Incident Herpes Zoster and Risk of Dementia: A Population-Based Danish Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  4. Patient-Centered Treatment of Chronic Migraine With Medication Overuse: More Is Not Always Better

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Vis graf over relationer

OBJECTIVE: Natalizumab inhibits the migration of systemic immune cells to the CNS and may be beneficial in progressive multiple sclerosis (MS). The objective of the study was to examine the effects of natalizumab in progressive MS.

METHODS: In an open-label phase 2A study, 24 patients with progressive MS were included to receive natalizumab treatment for 60 weeks. Response to natalizumab was assessed in CSF and MRI studies. The primary endpoint was change in CSF osteopontin, a biomarker of intrathecal inflammation, from baseline to week 60.

RESULTS: Seventeen patients completed the study. No new safety issues were encountered. CSF osteopontin decreased by 65 ng/mL (95% confidence interval 34-96 ng/mL; p = 0.0004) from baseline to week 60 in conjunction with decreases in other CSF biomarkers of inflammation, axonal damage, and demyelination. Magnetization transfer ratio increased in both cortical gray and normal-appearing white matter and correlated with decreases in CSF neurofilament light chain.

CONCLUSIONS: Natalizumab treatment of progressive MS reduces intrathecal inflammation and tissue damage, supporting a beneficial effect of natalizumab treatment in progressive MS and suggesting that systemic inflammation contributes to the pathogenesis. Moreover, the study establishes the feasibility of using CSF biomarkers in proof-of-concept trials, allowing a low number of participants and short study duration.

CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that in patients with progressive MS, natalizumab reduces biomarkers of intrathecal inflammation.

OriginalsprogEngelsk
TidsskriftNeurology
Vol/bind82
Udgave nummer17
Sider (fra-til)1499-507
Antal sider9
ISSN0028-3878
DOI
StatusUdgivet - 29 apr. 2014

ID: 44728211